美国血液学会2018年静脉血栓栓塞症管理指南:抗凝治疗的最佳管理
美国血液学会(ASH)基于GRADE方法制定循证指南,旨在支持患者、临床医生及其他医疗专业人员关于静脉血栓栓塞症(VTE)管理中抗凝药物使用的决策;指南假定抗凝药物选择已确定,最终形成25条推荐和2条良好实践声明。
要点
- 对于维生素K拮抗剂治疗,强烈推荐采用患者自我管理INR并结合家庭即时检测INR。
- 强烈推荐反对围手术期使用低分子量肝素(LMWH)桥接治疗。
- 有条件推荐包括:LMWH治疗剂量基于实际体重、不使用抗Xa因子监测指导LMWH剂量、使用专业抗凝管理服务、危及生命的出血事件后恢复抗凝。
核心结论
- 指南就优化接受抗凝药物治疗的VTE患者管理达成25条推荐和2条良好实践声明。
- 强推荐包括:维生素K拮抗剂治疗采用患者自我管理INR联合家庭即时检测INR;反对围手术期LMWH桥接治疗。
- 有条件推荐包括:LMWH治疗剂量基于实际体重;不使用抗Xa因子监测指导LMWH剂量;使用专业抗凝管理服务;危及生命的出血事件后恢复抗凝。
研究设计与样本
- ASH成立了多学科指南专家组,并平衡利益冲突以尽量减少潜在偏倚。
- 麦克马斯特大学GRADE中心支持指南制定过程,包括更新或执行系统证据评价。
- 专家组根据对临床医生和患者的重要性对临床问题和结局进行优先排序。
- 采用推荐分级的评估、制定与评价(GRADE)方法评估证据并制定推荐,推荐内容经过公开评论。
主要发现
- 专家组就优化接受抗凝药物治疗患者的管理达成25条推荐和2条良好实践声明。
关键数值与推荐
- 强推荐:维生素K拮抗剂治疗采用患者自我管理INR联合家庭即时检测INR。
- 强推荐:反对围手术期使用低分子量肝素(LMWH)桥接治疗。
- 有条件推荐:LMWH治疗剂量基于实际体重。
- 有条件推荐:不使用抗Xa因子监测指导LMWH剂量。
- 有条件推荐:使用专业抗凝管理服务;危及生命的出血事件后恢复抗凝。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinicians confront numerous practical issues in optimizing the use of anticoagulants to treat venous thromboembolism (VTE). OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians and other health care professionals in their decisions about the use of anticoagulants in the management of VTE. These guidelines assume the choice of anticoagulant has already been made. METHODS: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 25 recommendations and 2 good practice statements to optimize management of patients receiving anticoagulants. CONCLUSIONS: Strong recommendations included using patient self-management of international normalized ratio (INR) with home point-of-care INR monitoring for vitamin K antagonist therapy and against using periprocedural low-molecular-weight heparin (LMWH) bridging therapy. Conditional recommendations included basing treatment dosing of LMWH on actual body weight, not using anti-factor Xa monitoring to guide LMWH dosing, using specialized anticoagulation management services, and resuming anticoagulation after episodes of life-threatening bleeding.
引用
- Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018. PMID: 30482765. doi:10.1182/bloodadvances.2018024893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。